All Stories

  1. Национален консенсус за диагностика, лечение, проследяване и профилактика на хередитарната транстиретинова амилоидоза
  2. Национален консенсус за диагностика, лечение и профилактика на наследствените невромускулни заболявания
  3. From Phenotypes to Spectrum: Rethinking RRMS, SPMS and PPMS in the Era of PIRA—A Framework Integrating PIRA, Smouldering-Associated Worsening, and Neurologic Reserve to Facilitate Earlier Recognition of Progression
  4. Зонизамид (Zonisamide) - нова възможност за лечение на епилепсиите в България
  5. Национален консенсус за диагностика и лечение на myasthenia gravis
  6. Национален консенсус за диагностика и лечение на епилепсията
  7. First steps in the treatment of advanced Parkinson’s disease with foslevodopa/foscarbidopa continuous subcutaneous infusion
  8. Prevalence and Associations of Poor Sleep in Patients with Relapsing-Remitting Multiple Sclerosis on Disease-Modifying Therapy
  9. Differences in acute ischemic stroke treatment: A cross-sectional study from international Registry of Stroke Care Quality (RES-Q)
  10. Лечение на болката при диабетна полиневропатия
  11. Обективно измерване и анализ на параметри на походката при пациенти с болестта на Паркинсон
  12. Национален консенсус за диагностика и лечение на myasthenia gravis
  13. Национален консенсус за профилактика, диагноза и лечение на мозъчносъдовите заболявания
  14. Съвременно лечение на миастения гравис
  15. Нумуларно главоболие – клиничен случай
  16. Синдром на неспокойните крака
  17. Актуална терминология, диагностициране и възможности за съвременно лечение
  18. Болки в шията
  19. Национален консенсус за диагностика и лечение на епилепсия
  20. Национален консенсус за диагностика, лечение, проследяване и профилактика на хередитарната транстиретиновата амилоидоза
  21. Консенсус за диагностика и лечение на болестите с натрупване в лизозомите с неврологични изяви
  22. Национален консенсус за диагностика, лечение, проследяване и профилактика на хередитарната транстиретинова амилоидоза
  23. Национален консенсус за диагностика и лечение на myasthenia gravis
  24. Thermodynamic Signatures of Blood Plasma Proteome in Neurodegenerative Pathologies
  25. Eficacia en la vida real del fingolimod en pacientes con esclerosis múltiple en Bulgaria
  26. Platelets’ Nanomechanics and Morphology in Neurodegenerative Pathologies
  27. Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial
  28. Efficacy and safety of adjunctive cenobamate: Post-hoc analysis of study C017 in patients grouped by mechanism of action of concomitant antiseizure medications
  29. Morphometry and Stiffness of Red Blood Cells—Signatures of Neurodegenerative Diseases and Aging
  30. Red Blood Cells’ Thermodynamic Behavior in Neurodegenerative Pathologies and Aging
  31. The development and use of the European academy of neurology guideline on palliative care in advanced progressive multiple sclerosis
  32. Translation, adaptation and validation of the Bulgarian version of the King’s Parkinson’s Disease Pain Scale
  33. Clinical Correlation between Hormonal Status and Autonomic Nervous System Function in Patients with Fibromyalgia
  34. Structured headache services as the solution to the ill-health burden of headache: 1. Rationale and description
  35. Consensus guidelines for botulinum toxin therapy: general algorithms and dosing tables for dystonia and spasticity
  36. EAN Guideline on Palliative Care of People with Severe, Progressive Multiple Sclerosis
  37. Neurophysiological Findings in Chronic Pain Syndromes
  38. Repetitive Transcranial Magnetic Stimulation over Two Target Areas, Sham Stimulation and Topiramate in the Treatment of Chronic Migraine
  39. Pitfals in recognition and management of trigeminal neuralgia
  40. Palliative care in multiple sclerosis: European guideline
  41. EAN guideline on palliative care of people with severe, progressive multiple sclerosis
  42. Safety of adjunctive treatment with cenobamate in patients with uncontrolled focal seizures – Authors' reply
  43. Update on the Management of Parkinson’s Disease for General Neurologists
  44. Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial
  45. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial
  46. Novel Approach for Objective Quantification of Locomotor Disturbaces in Low Back Pain
  47. Neutralizing Antibodies against Interferon‑beta in Bulgarian Adolescent Multiple Sclerosis Patients
  48. Patient and caregiver involvement in the formulation of guideline questions: findings from the European Academy of Neurology guideline on palliative care of people with severe multiple sclerosis
  49. Do Binding Antibodies Predict Neutralizing Antibody Development in Multiple Sclerosis Patients?
  50. Starvation, Strachan's syndrome, and postgastroplasty syndrome
  51. Management of dystonia in Europe: a survey of the European network for the study of the dystonia syndromes
  52. F-Wave in the Upper Extremities of Patients with Primary Torsion Dystonia
  53. Serum levels of EBVNA-IgG and EBVCA-IgG in patients with multiple sclerosis
  54. Trigeminal Nerve Reflexes in Chronic Pain Syndromes
  55. Back pain
  56. Back pain
  57. Trigeminal Neuralgia
  58. Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study
  59. ExtaviJect® 30G device for subcutaneous self-injection of interferon beta-1b for multiple sclerosis: a prospective European study
  60. Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage
  61. Diagnostic value of combinations of symptoms of migraine and tension-type headache included in the diagnostic criteria for children and adolescents in the international classification of headache disorders 2nd edition
  62. Chromosomal radiosensitivity in patients with multiple sclerosis
  63. How Does Fingolimod (Gilenya®) Fit in the Treatment Algorithm for Highly Active Relapsing-Remitting Multiple Sclerosis?
  64. Evaluation of diagnostic and prognostic value of clinical characteristics of Migraine and Tension type headache included in the diagnostic criteria for children and adolescents in International Classification of Headache Disorders - second edition
  65. Fingolimod in the treatment algorithm of relapsing remitting multiple sclerosis: a statement of the Central and East European (CEE) MS Expert Group
  66. Placebo-Controlled Trial of Oral Laquinimod for Multiple Sclerosis
  67. Prevalence of Dementia and Mild Cognitive Impairment in a Bulgarian Urban Population
  68. A basic diagnostic headache diary (BDHD) is well accepted and useful in the diagnosis of headache. A multicentre European and Latin American study
  69. Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trial
  70. Implementation and impact of headache guidelines
  71. Double‐blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson's disease
  72. Rapid benefits of a new formulation of subcutaneous interferon beta-1a in relapsing—remitting multiple sclerosis
  73. A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis
  74. Transient Mutism and Pathologic Laughter in the Course of Cerebellitis
  75. Mechanisms of tizanidine action on spasticity
  76. Mechanisms of baclofen action on spasticity
  77. Rationale and Design of a Randomized, Double-Blind, Parallel-Group Study of Terutroban 30 mg/day versus Aspirin 100 mg/day in Stroke Patients: The Prevention of Cerebrovascular and Cardiovascular Events of Ischemic Origin with Terutroban in Patients wi...
  78. Determination of plasma aminothiols by high performance liquid chromatography after precolumn derivatization with N-(2-acridonyl)maleimide
  79. P013 Neurophysiological study on facial F-waves in patients with primary headache and with Parkinson's disease
  80. P234 Monitoring of drug efficacy on different types of tremor in Parkinson's disease
  81. Phase 2 trial of a DNA vaccine encoding myelin basic protein for multiple sclerosis
  82. Therapeutic Use of Nicergoline
  83. S.01.02 Tension-type headache
  84. 1.184 Cognitive impairments in patients with early Parkinson's disease
  85. Abnormal Modulatory Influence of Diffuse Noxious Inhibitory Controls in Migraine and Chronic Tension-Type Headache Patients
  86. The epidemiology of multiple sclerosis in Europe
  87. International Prevalence, Recognition, and Treatment of Cardiovascular Risk Factors in Outpatients With Atherothrombosis
  88. Acute reversible parkinsonism in Epstein–Bbarr virus–related encephalitis lethargica‐like illness
  89. Pain and tension-type headache: a review of the possible pathophysiological mechanisms
  90. Lower limb SSEP changes in stroke—predictive values regarding functional recovery
  91. Electrophysiological evidence for trigeminal neuron sensitization in patients with migraine.
  92. Trigemino-Cervical Reflex in Patients with Headache
  93. Clinical and electromyographic assessment of essential tremor treatment
  94. Antiphospholipid syndrome and dystonia-parkinsonism
  95. Electrophysiological evidence for trigeminal neuron sensitization in patients with migraine
  96. Antiphospholipid syndrome and dystonia-parkinsonism
  97. Electromyographic differentiation of tremors
  98. A cross-over clinical and electromyographic assessment of treatment for parkinsonian tremor
  99. Clinical and electromyographic examinations of patients with tremor after chronic occupational lead exposure
  100. Antiphospholipid syndrome and dystonia–parkinsonism. A case report
  101. Prevalence of Parkinson’s Disease in Bulgaria
  102. Effects of Sleep on Spinal Nociceptive Reflexes in Humans
  103. Clinical and electromyographic examinations of Parkinsonian tremor
  104. Asymmetrical reduction of the nociceptive flexion reflex threshold in cluster headache
  105. Asymmetrical Reduction of the Nociceptive Flexion Reflex Threshold in Cluster Headache
  106. Acupuncture for episodic tension-type headache: a multicentre randomized controlled trial
  107. Effects of hypnosis on diffuse noxious inhibitory controls
  108. Clinical and electromyographic characteristics of tremor in patients with depression
  109. Clinical and Electromyographic Examinations of Patients with Essential Tremor
  110. Prevalence of Parkinson’s Disease in Bulgarian Gypsies
  111. Neurophysiological approach to the study of cluster headache
  112. Different effect of high doses of naloxone on spinal reflexes in normal subjects and chronic paraplegic patients
  113. Prevalence of Multiple Sclerosis in Gypsies and Bulgarians
  114. Contralateral hemi-parkinsonism and atypical tremor after stroke (a case report)
  115. Parkinsonian Syndrome as a Neurological Manifestation of Behcet's Disease
  116. 1-02-06 Differential diagnosis of amyotrophic lateral sclerosis and similar syndromes
  117. Prevalence of Multiple Sclerosis in Bulgaria
  118. P169 Differential diagnosis of limb girdle syndromes
  119. Writer’s Cramp and Tremor Due to Brain Tumor
  120. Vestibular and auditory influences on segmental motoneuron excitability — a comparative study
  121. Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Gammopathy and Skin Changes (Poems) Syndrome
  122. A comparative study of methods for estimation of presynaptic inhibition
  123. A Comparison of Methods to Assess the Excitability of Lower Motoneurones